University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

May 06, 2021

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

May 03, 2021

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

April 30, 2021

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

April 23, 2021

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

April 20, 2021

Michael R. Charlton, MD, MBBS, discusses the effects of the COVID-19 pandemic on hepatocellular carcinoma.

August 21, 2020

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

May 22, 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

May 21, 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

May 18, 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

May 14, 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

May 13, 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

May 12, 2020

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

April 20, 2020

Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.

April 16, 2020

This week we have collaborated with The University of Chicago Medicine to highlight important topics facing oncologists today. Join us Saturday, May 16, 2020 at 11 AM EST.

April 16, 2020

This week we have collaborated with The University of Chicago Medicine to highlight important topics facing oncologists today. Join us Saturday, May 16, 2020 at 11 AM EST.

March 31, 2020

Jessica Donington, MD, MSCR, discusses the effectiveness of neoadjuvant immunotherapy and how it compares with neoadjuvant chemotherapy in patients with lung cancer.

March 05, 2020

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

February 06, 2020

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

December 07, 2019

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

November 27, 2019

Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.